A Smart Play for Small Biotech: Australia's Edge in Early-Phase Trials
As an early-phase CRO, Complete Phase sees the global bottlenecks—cost, time, regulatory drag. In Australia, many fade: faster start-up, more flexibility, strong regulatory credibility, and often lower costs. This webinar shows U.S. biotech/pharma and clinical ops leaders why Australia is a rising Phase I/II hub—move fast, control budgets, and deliver FDA/EMA-ready data.
Audience: Small–mid-size biotech & pharma leaders (Clinical Ops, R&D, founders, budget owners)
Register for Webinar
When:
Oct 15, 2:30 PM PT / Oct 15, 5:30 PM ET
Format:
Live panel with experts from AU / US
Host:
Complete Phase (CRO)
Topics: In 30 minutes you'll learn:
Fast start-up via HREC + TGA CTN
(rigor without drag)
Costs & incentives for early phase
Global-ready data: ICH-GCP; FDA/EMA acceptance
Risks & fixes: import/export, time zones, alignment—with a local CRO
Patient enrollment: Speed & Diversity in Australia
Speakers
To be announced (AU/US)
Registration
Don't miss your chance on October 15, 2:30 PM PT. We'll show you how working with a CRO in Australia can transform your early-phase trial execution — with speed, quality, and cost advantages you won't want to ignore.
Register for Webinar